QQQ   310.73 (-0.32%)
AAPL   155.94 (+3.39%)
MSFT   262.05 (-0.96%)
META   193.00 (+2.24%)
GOOGL   106.89 (-0.79%)
AMZN   107.65 (-4.66%)
TSLA   196.23 (+4.23%)
NVDA   214.97 (-0.98%)
NIO   11.58 (-3.18%)
BABA   106.89 (-2.60%)
AMD   87.64 (-0.76%)
T   19.89 (-1.92%)
F   13.43 (-6.22%)
MU   63.23 (+0.09%)
CGC   3.03 (-3.50%)
GE   82.92 (-1.22%)
DIS   112.10 (-0.98%)
AMC   6.63 (+9.05%)
PFE   44.21 (-0.29%)
PYPL   87.17 (+0.24%)
NFLX   375.45 (+2.33%)
QQQ   310.73 (-0.32%)
AAPL   155.94 (+3.39%)
MSFT   262.05 (-0.96%)
META   193.00 (+2.24%)
GOOGL   106.89 (-0.79%)
AMZN   107.65 (-4.66%)
TSLA   196.23 (+4.23%)
NVDA   214.97 (-0.98%)
NIO   11.58 (-3.18%)
BABA   106.89 (-2.60%)
AMD   87.64 (-0.76%)
T   19.89 (-1.92%)
F   13.43 (-6.22%)
MU   63.23 (+0.09%)
CGC   3.03 (-3.50%)
GE   82.92 (-1.22%)
DIS   112.10 (-0.98%)
AMC   6.63 (+9.05%)
PFE   44.21 (-0.29%)
PYPL   87.17 (+0.24%)
NFLX   375.45 (+2.33%)
QQQ   310.73 (-0.32%)
AAPL   155.94 (+3.39%)
MSFT   262.05 (-0.96%)
META   193.00 (+2.24%)
GOOGL   106.89 (-0.79%)
AMZN   107.65 (-4.66%)
TSLA   196.23 (+4.23%)
NVDA   214.97 (-0.98%)
NIO   11.58 (-3.18%)
BABA   106.89 (-2.60%)
AMD   87.64 (-0.76%)
T   19.89 (-1.92%)
F   13.43 (-6.22%)
MU   63.23 (+0.09%)
CGC   3.03 (-3.50%)
GE   82.92 (-1.22%)
DIS   112.10 (-0.98%)
AMC   6.63 (+9.05%)
PFE   44.21 (-0.29%)
PYPL   87.17 (+0.24%)
NFLX   375.45 (+2.33%)
QQQ   310.73 (-0.32%)
AAPL   155.94 (+3.39%)
MSFT   262.05 (-0.96%)
META   193.00 (+2.24%)
GOOGL   106.89 (-0.79%)
AMZN   107.65 (-4.66%)
TSLA   196.23 (+4.23%)
NVDA   214.97 (-0.98%)
NIO   11.58 (-3.18%)
BABA   106.89 (-2.60%)
AMD   87.64 (-0.76%)
T   19.89 (-1.92%)
F   13.43 (-6.22%)
MU   63.23 (+0.09%)
CGC   3.03 (-3.50%)
GE   82.92 (-1.22%)
DIS   112.10 (-0.98%)
AMC   6.63 (+9.05%)
PFE   44.21 (-0.29%)
PYPL   87.17 (+0.24%)
NFLX   375.45 (+2.33%)
OTCMKTS:ABVC

ABVC BioPharma - ABVC Stock Forecast, Price & News

$0.71
-0.02 (-2.74%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.70
▼
$0.74
50-Day Range
$0.60
▼
$1.07
52-Week Range
$0.50
▼
$3.13
Volume
68,010 shs
Average Volume
2.45 million shs
Market Capitalization
$23.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ABVC stock logo

About ABVC BioPharma (OTCMKTS:ABVC) Stock

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.

Receive ABVC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter.

ABVC Stock News Headlines

January 19, 2023 | finance.yahoo.com
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
January 18, 2023 | finance.yahoo.com
ABVC: Several Potential Paths to Achieving Near-Term Milestones
February 3, 2023 | Investing Trends (Ad)
The Humble Mineral at the Heart of the EV Revolution (Not Lithium)
You may know of graphite as what's in the tip of a No. 2 pencil, but it is the key to many forms of renewable energy. Today, this humble mineral is at the epicenter of the electric car revolution. Because what most people don't know is today's EV batteries contain more than 220 pounds of graphite – more than lithium, copper or aluminum!
January 5, 2023 | msn.com
What's Happening With ABVC BioPharma Shares?
January 5, 2023 | finance.yahoo.com
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer
December 20, 2022 | finance.yahoo.com
ABVC: Key Medical Venues Participating in Clinical Studies
November 17, 2022 | finance.yahoo.com
ABVC BioPharma Third Quarter 2022 Earnings: Beats Expectations
November 17, 2022 | finance.yahoo.com
ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval
February 3, 2023 | Investing Trends (Ad)
The Humble Mineral at the Heart of the EV Revolution (Not Lithium)
You may know of graphite as what's in the tip of a No. 2 pencil, but it is the key to many forms of renewable energy. Today, this humble mineral is at the epicenter of the electric car revolution. Because what most people don't know is today's EV batteries contain more than 220 pounds of graphite – more than lithium, copper or aluminum!
November 16, 2022 | finanznachrichten.de
ABVC BioPharma, Inc.: ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results
November 15, 2022 | finance.yahoo.com
ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results
November 7, 2022 | finance.yahoo.com
ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)
November 2, 2022 | finance.yahoo.com
Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma’s Medication for Treating Depression in Cancer Patients
October 5, 2022 | finance.yahoo.com
ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia
September 25, 2022 | seekingalpha.com
ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug
September 16, 2022 | finance.yahoo.com
ABVC: Moving Lead Assets Forward and Expanding Development Pipeline
September 13, 2022 | finance.yahoo.com
ABVC Biopharma Announces Letter to Shareholders
September 9, 2022 | finance.yahoo.com
ABVC BioPharma Selects Additional Vitargus® Phase II Study Site
September 7, 2022 | reuters.com
ABVC Biopharma Inc
August 22, 2022 | finance.yahoo.com
ABVC Provides Oncology Pipeline Updates
August 20, 2022 | marketwatch.com
ABVC BioPharma Provides Vitargus(R) Update
August 19, 2022 | seekingalpha.com
ABVC BioPharma Vitargus phase 2 protocol study cleared by Thai hospital ethics committee
August 18, 2022 | nasdaq.com
Is ABVC BioPharma (NASDAQ:ABVC) Using Debt In A Risky Way?
August 18, 2022 | apnews.com
ABVC BioPharma Provides Vitargus Update
August 16, 2022 | finance.yahoo.com
ABVC BioPharma Reports Second Quarter 2022 Financial and Operational Results
July 18, 2022 | finance.yahoo.com
ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028
July 15, 2022 | seekingalpha.com
ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial
See More Headlines
Receive ABVC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter.

ABVC Company Calendar

Last Earnings
11/14/2022
Today
2/03/2023
Next Earnings (Estimated)
3/29/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ABVC
CUSIP
N/A
CIK
1173313
Web
www.ambrivis.com
Phone
(510) 668-0881
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.68)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-12,840,000.00
Net Margins
N/A
Pretax Margin
-5,208.75%
Return on Equity
-248.85%
Return on Assets
-154.72%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.75
Quick Ratio
0.74

Sales & Book Value

Annual Sales
$360,000.00
Price / Sales
64.35
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.31 per share
Price / Book
2.29

Miscellaneous

Outstanding Shares
32,630,000
Free Float
18,470,000
Market Cap
$23.17 million
Optionable
Not Optionable
Beta
0.46

Key Executives

  • Eugene Jiang
    Chairman & Chief Business Officer
  • Howard Doong
    President & Chief Executive Officer
  • Leeds Chow
    Chief Financial Officer & Accounting Officer
  • Chi-Hsin King
    Chief Scientific Officer
  • Tsung-Shann Jiang
    Director & Chief Strategy Officer

Key Competitors

View All Competitors













ABVC Stock - Frequently Asked Questions

Should I buy or sell ABVC BioPharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ABVC BioPharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ABVC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABVC, but not buy additional shares or sell existing shares.
View ABVC analyst ratings or view top-rated stocks.

How have ABVC shares performed in 2023?

ABVC BioPharma's stock was trading at $0.6250 on January 1st, 2023. Since then, ABVC stock has increased by 13.6% and is now trading at $0.71.
View the best growth stocks for 2023 here.

When is ABVC BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our ABVC earnings forecast.

How were ABVC BioPharma's earnings last quarter?

ABVC BioPharma, Inc. (OTCMKTS:ABVC) issued its quarterly earnings data on Monday, November, 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.09. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.03 million.

What is ABVC BioPharma's stock symbol?

ABVC BioPharma trades on the OTCMKTS under the ticker symbol "ABVC."

How do I buy shares of ABVC BioPharma?

Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ABVC BioPharma's stock price today?

One share of ABVC stock can currently be purchased for approximately $0.71.

How much money does ABVC BioPharma make?

ABVC BioPharma (OTCMKTS:ABVC) has a market capitalization of $23.17 million and generates $360,000.00 in revenue each year. The company earns $-12,840,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

How can I contact ABVC BioPharma?

ABVC BioPharma's mailing address is 44370 Old Warm Springs Blvd, Fremont CA, 94538. The official website for the company is www.ambrivis.com. The company can be reached via phone at (510) 668-0881.

This page (OTCMKTS:ABVC) was last updated on 2/3/2023 by MarketBeat.com Staff